摘要
<strong>Background:</strong> <span style="font-family:Verdana;">Breast cancer (BC) is considered the most common women cancer worldwide. </span><span style="font-family:Verdana;">The main clinicopathological prognostic factors are tumor size, lymph node status and estrogen/progesterone (ER/PR) receptor status</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;"> In addition, some factors are both prognostic and predictive as ER/PR receptors and HER2/neu overexpression. </span><span style="font-family:Verdana;">Axillary lymph node status is the most important prognostic factor for breast cancer. Node negative breast cancer patients had the best 5-year overall survival (OS) of 82.8% compared to 73%, 45.7%, and 28.4% for patients with 1</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">-</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">3, 4</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">-</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">12, and ≥13 positive nodes, respectively. </span><span style="font-family:Verdana;">The aim of this study was</span><span style="font-family:Verdana;"> to determine the association between different clinicopathological features and </span><span style="font-family:Verdana;">development</span><span style="font-family:Verdana;"> of metastasis in a group of Egyptian women with early breast cancer</span></span><span style="font-family:Verdana;">,</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> also, to assess patients’ Relapse-free survival (DFS) and OS and their correlation with different clinicopathological features. </span><b><span style="font-family:Verdana;">Patients and Methods: </span></b><span style="font-family:Verdana;">We retrospectively reviewed the files of breast cancer patients who were treated and </span><span style="font-family:Verdana;">followed-up</span><span style="font-family:Verdana;"> at the clinical oncology department and surgical oncology unit, Alexandria Main University Hospital during the period from January 2014 to December 2017. A total of 1848 breast cancer cases were presented during this </span><span style="font-family:Verdana;">period of time</span><span style="font-family:Verdana;">. 141 out of the 1848 patients developed metastasis from breast cancer during follow-up. Among the 141 patients, only 102 had adequate clinical, pathological, treatment </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> follow-up data enough for analysis and were included in our study. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">The number of patients who developed distant metastasis from breast cancer during the study period (metachronous metastasis) ranges from 17</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">-</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">31 cases/year. All the study patients had documented metastatic disease constituting 102 out of 1848 collected patients representing about 5.5%. The median time for </span><span style="font-family:Verdana;">development</span><span style="font-family:Verdana;"> of metastasis from the initial diagnosis among the 102 studied patients was 17.88 months. Seventy-two out of 102 cases had </span><span style="font-family:Verdana;">distant</span><span style="font-family:Verdana;"> recurrence. There was </span></span><span style="font-family:Verdana;">a </span><span style="font-family:Verdana;">significant</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> correlation between DFS and tumor size, grade, number of lymph nodes involved </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> hormone receptor (ER and PR) status. Age, tumor grade, tumor size </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> Her2 status had </span></span><span style="font-family:Verdana;">a </span><span style="font-family:Verdana;">significant</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> impact on the OS. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">The clinicopathological characteristics of the primary tumor are important for predicting the risk of metastasis among early breast cancer patients and determining their prognosis.</span></span>
<strong>Background:</strong> <span style="font-family:Verdana;">Breast cancer (BC) is considered the most common women cancer worldwide. </span><span style="font-family:Verdana;">The main clinicopathological prognostic factors are tumor size, lymph node status and estrogen/progesterone (ER/PR) receptor status</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;"> In addition, some factors are both prognostic and predictive as ER/PR receptors and HER2/neu overexpression. </span><span style="font-family:Verdana;">Axillary lymph node status is the most important prognostic factor for breast cancer. Node negative breast cancer patients had the best 5-year overall survival (OS) of 82.8% compared to 73%, 45.7%, and 28.4% for patients with 1</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">-</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">3, 4</span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">-</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">12, and ≥13 positive nodes, respectively. </span><span style="font-family:Verdana;">The aim of this study was</span><span style="font-family:Verdana;"> to determine the association between different clinicopathological features and </span><span style="font-family:Verdana;">development</span><span style="font-family:Verdana;"> of metastasis in a group of Egyptian women with early breast cancer</span></span><span style="font-family:Verdana;">,</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> also, to assess patients’ Relapse-free survival (DFS) and OS and their correlation with different clinicopathological features. </span><b><span style="font-family:Verdana;">Patients and Methods: </span></b><span style="font-family:Verdana;">We retrospectively reviewed the files of breast cancer patients who were treated and </span><span style="font-family:Verdana;">followed-up</span><span style="font-family:Verdana;"> at the clinical oncology department and surgical oncology unit, Alexandria Main University Hospital during the period from January 2014 to December 2017. A total of 1848 breast cancer cases were presented during this </span><span style="font-family:Verdana;">period of time</span><span style="font-family:Verdana;">. 141 out of the 1848 patients developed metastasis from breast cancer during follow-up. Among the 141 patients, only 102 had adequate clinical, pathological, treatment </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> follow-up data enough for analysis and were included in our study. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">The number of patients who developed distant metastasis from breast cancer during the study period (metachronous metastasis) ranges from 17</span></span><span style="font-family:;" "=""> </span><span style="font-family:Verdana;">-</span><span style="font-family:;" "=""> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">31 cases/year. All the study patients had documented metastatic disease constituting 102 out of 1848 collected patients representing about 5.5%. The median time for </span><span style="font-family:Verdana;">development</span><span style="font-family:Verdana;"> of metastasis from the initial diagnosis among the 102 studied patients was 17.88 months. Seventy-two out of 102 cases had </span><span style="font-family:Verdana;">distant</span><span style="font-family:Verdana;"> recurrence. There was </span></span><span style="font-family:Verdana;">a </span><span style="font-family:Verdana;">significant</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> correlation between DFS and tumor size, grade, number of lymph nodes involved </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> hormone receptor (ER and PR) status. Age, tumor grade, tumor size </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> Her2 status had </span></span><span style="font-family:Verdana;">a </span><span style="font-family:Verdana;">significant</span><span style="font-family:;" "=""><span style="font-family:Verdana;"> impact on the OS. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">The clinicopathological characteristics of the primary tumor are important for predicting the risk of metastasis among early breast cancer patients and determining their prognosis.</span></span>